Table 1.
Baseline characteristics of patients in pre-neoadjuvant chemotherapy status.
| Characteristics | No. (%) |
|---|---|
| Age | |
| Mean ± SD | 46.5 (±9.1) |
| Clinical stage | |
| II | 65 (45.1) |
| III | 79 (54.9) |
| Clinical T stage | |
| T1–T2 | 77 (53.5) |
| T3–T4 | 67 (46.5) |
| Clinical N stage | |
| N0 | 29 (20.1) |
| N1–N3 | 115 (79.9) |
| Histologic subtype | |
| IDC | 129 (89.6) |
| ILC | 6 (4.2) |
| Others | 9 (6.2) |
| Histologic grade | |
| Low to intermediate | 98 (68.1) |
| High | 46 (31.9) |
| Estrogen receptor | |
| Positive | 107 (74.3) |
| Negative | 37 (25.7) |
| Progesterone receptor | |
| Positive | 90 (62.5) |
| Negative | 54 (37.5) |
| HER2 status | |
| Negative | 113 (78.5) |
| Positive | 31 (21.5) |
| Molecular subtype | |
| Luminal A | 43 (29.9) |
| Luminal B | 64 (44.4) |
| HER2+ | 15 (10.4) |
| Triple-negative | 22 (15.3) |
| Ki-67 proliferation index | |
| <20% | 65 (45.1) |
| ≥20% | 79 (54.9) |
| NAC regimen | |
| AC | 42 (29.2) |
| AD | 32 (22.2) |
| ACT | 70 (48.6) |
IDC, invasive ductal carcinoma; ILC, invasive lobular carcinoma; HER2, human epidermal growth factor receptor 2; NAC, neoadjuvant chemotherapy; AC, doxorubicin plus cyclophosphamide; AD, doxorubicin plus docetaxel; AC-T, AC followed by docetaxel.